Marlinz Pharma closed the 2023 year with another record for double-digit revenue growth and total annual revenues, including growth across all sectors and continued market penetration with its Therapeutic and, maintenance and prevention foot soaks. Marlinz Pharma now has over 4500 dispensing practices and clinics across the United States and Canada and plans to expand into Europe in 2025. Our R&D pipeline is expanding, and new FDA Phase Two trials will be published later this year. Through our healthcare partners, we have now dispensed over 1.6M units of Tolcylen products directly to patients, in many cases eliminating the need for high-cost Rx drugs that can have low efficacy rates and sometimes be complex to get covered by typical insurance policies.
Marlinz Pharma Reaches New Milestones to Close Out a Successful 2023
